Earlier this month, Janssen/Pharmacyclics announced they had submitted a New Drug Application (NDA) for Food & Drug Administration (FDA) approval

 Ibrutinib leads the race to CLL 17p deletion market

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $129 a month (THIS SUBSCRIPTION AUTOMATICALLY BILLS YOUR CREDIT CARD EACH MONTH UNTIL YOU CANCEL) or $327 for 3 months access (does not auto renew), $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if a communications professional our Guidance to PR Professionals contained within it.